Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TCK 276

Next Previous
Drug Profile

TCK 276

Alternative Names: TCK-276

Latest Information Update: 01 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teijin Pharma
  • Class Antirheumatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Phase I Rheumatoid arthritis

Most Recent Events

  • 10 Nov 2023 Pharmacokinetics and adverse events data from a phase-I clinical trials in Rheumatoid arthritis presented at the ACR Convergence 2023 (ACR-ARP-2023)
  • 27 Jul 2023 Teijin America completes a phase I trial in Rheumatoid arthritis in USA (PO) (NCT05437419)
  • 28 Mar 2023 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Japan (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top